Early Phase 1 N=116 18F-DCFBC PET/CT in Prostate Cancer
Prostatic Neoplasms · Prostate Cancer
Primary: Number of Participants With Local Recurrence, Lymph Node Metastases or Distant Metastatic Sites Detected by…
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=30 Does Intravenous Lactated Ringer Solution Raise Measured Serum Lactate?
Hyperlactatemia
Primary: Change in Mean Lactate Level of the LR Group Compared to the NS Group. — 0.93; 0.37 mmol/L
Early Phase 1 N=18 Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer
Active Cocaine Users
Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 0.06; 0.94; 0.75; 0.88 cocaine choices
Early Phase 1 N=24 Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue
Breast Cancer
Primary: Number of Participants With Spot 14 Expression Pre and Post CLA as Assessed by Quantitative Immunohistochemistry and Staining Intensities Scored at 0, 1, or 2 — 0; 0…
Early Phase 1 N=20 Cabergoline in Metastatic Breast Cancer
Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Overall Response Rate (ORR) at 2 Months — 0 Participants
Early Phase 1 N=28 D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder
Body Dysmorphic Disorder
Primary: Body Dysmorphic Disorder Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS) — 19.64; 18.77 units on a scale
Early Phase 1 N=19 Intensity Modulated Radiation Therapy for Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Any Grade 2 Toxicity Using Intensity Modulated Radiation Therapy (IMRT) to Treat the At-risk Lymph Nodes in Prostate Cancer ( up to First 10…
Early Phase 1 N=37 Biomarker Study in Participants With Migraine
Migraine Disorders
Primary: The Capsaicin-Induced Dermal Blood Flow (DBF) — 606.1; 599.5; 689.2 Flux mean
Early Phase 1 N=6 Investigation of Female Reproductive Hormone Dynamics During Adolescence
Menstruation Disturbances
Primary: Ovulation in Cycle 2 — 3; 2 Participants
Early Phase 1 N=26 Concentration and Activity of Lapatinib in Vestibular Schwannomas
Vestibular Schwannoma · NF2 · Neurofibromatosis 2
Primary: Median Steady-state Lapatinib Plasma Concentrations at the Time of Surgical Resection — 3149 ng/mL
Early Phase 1 N=6 Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
Blood Brain Barrier Defect
Primary: Change in AUC0-18 of the Temozolomide Concentration (AUC-T) in Brain Interstitium Before and After Regadenoson Infusion — 19.1; 18.0 percentage of AUC
Early Phase 1 N=12 Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis
Fatigue · Overheating
Primary: Change in Time to Exhaustion — 568; 552 seconds
Early Phase 1 N=10 Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes
Type 1 Diabetes
Primary: Percent Change From Baseline in IL-6 Stimulated Intracellular p-STAT3 at Week 12 — -4.31 Percent change from Baseline
Early Phase 1 N=9 A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
Prostate Cancer
Primary: The Proportion of mCRPC Patients Treated With Vismodegib Who Achieve a Pharmacodynamic (PD) Response in Tumor Biopsies — 7 Participants
Early Phase 1 N=22 Phytosterols, Ezetimibe, and Cholesterol Metabolism
Hypercholesterolemia · Coronary Heart Disease
Primary: Cholesterol Excretion — 505; 794; 962 mg per day — p=0.01